Provectus Biopharmaceuticals Announces Synthesis of New Halogenated Xanthene Small Molecule
Provectus recently announced it has successfully developed and manufactured a second halogenated xanthene (HX), adding to its lead, clinical-stage, HX small molecule called rose bengal sodium (RBS). The molecular name of the newly synthesized HX is 4,5,6,7-tetrabromo-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenz- ofuran-1,9′-xanthen]-3-one.
Provectus’ intellectual property estate comprises an entire class of proprietary, related HX molecules that are proprietarily synthesized using Quality-by-Design principles (QbD) under current Good Manufacturing Practice (cGMP) and International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines.
Dominic Rodrigues, Vice Chair of the company’s Board of Directors, said “Different permutations and combinations of halogen atoms on the backbone of this molecular class convey different biological, chemical, and/or physical properties to each class member. We are excited to have produced a new halogenated xanthene, further expanding our medical science platform. We look forward to developing this small molecule into a viable Provectus drug product candidate.”
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes. Multi-route of administration drug discovery and development programs include investigational drugs and drug targets in oncology (clinical-stage), dermatology (clinical-stage), hematology, virology, microbiology, ophthalmology (clinical-stage), and animal health. Information about the company’s clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For more information, visit www.provectusbio.com.
Total Page Views: 737
